Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Dipyridamole
Drug: Aggrenox
Drug: Lansoprazole
Drug: Aspirin

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 31

Registration Number: NCT02251184

Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir
Drug: Ritonavir
Drug: Darunavir
Drug: Aspirin

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 52

Registration Number: NCT02251795

Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TPV + RTV (low dose)
Drug: TPV + RTV (high dose)
Drug: ddl

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 50

Registration Number: NCT02251873

Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir
Drug: Ritonavir
Drug: Rifabutin

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02251171

Pharmacokinetics of Tipranavir Soft Elastic Capsules (SEDDS) and Ritonavir and Their Effects on Cytochrome P-450 (3A4) in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TPV low 2
Drug: TPV medium
Drug: TPV high 1
Drug: TPV low 1
Drug: TPV high 2
Drug: Ritonavir high
Drug: RTV low
Drug: Radiolabelled erythromycin

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 113

Registration Number: NCT02251132

Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir oral solution
Drug: Tipranavir capsules
Drug: Ritonavir soft gel capsules
Drug: Ritonavir oral solution
Other: High fat breakfast

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02251158

Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir high dose
Drug: Tipranavir low dose
Drug: Ritonavir high dose
Drug: Ritonavir low dose
Drug: Tenofovir disoproxil fumarate

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 49

Registration Number: NCT02251145

Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir
Drug: Ritonavir
Drug: Clarithromycin
Other: High-Fat Test Meal

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02251769

The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir
Drug: Ritonavir
Drug: Loperamide

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02251119

Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke

Phase 2

Completed

Conditions: Stroke

Interventions: Drug: Placebo
Drug: BIII 890 CL

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 97

Registration Number: NCT02251197

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy